MOBILE Trial design: Patients with critical limb ischemia were randomized to intramuscular injection of bone marrow-derived stem cells (n = 119) vs. placebo.

Slides:

Advertisements

Similar presentations

What is REGENERATIVE MEDICINE? “The regeneration or replacement of cells, tissues or organs to restore or establish normal function.” The goal is to.

Advertisements

{ R. Diaz-Garcia MD, J. Bernardo MD Stem Cell Therapy for Patients with Critical Limb Ischemia: A Meta-analysis with Critical Limb Ischemia: A Meta-analysis.

Limbs International Medical Buflomedil Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Alain Leizorovicz LIMB.

EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.

(p for noninferiority = 0.01)

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Copyright © 2009 American Medical Association. All rights reserved.

Fig 1: Microscopic Spindle shaped MSCs Fig 2: Method of MSCs Injection

Harrison CN et al. Proc ASH 2015;Abstract 59.

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

Phase 2 Treatment Naïve Injection Drug Use

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

TECAM Trial design: STEMI patients who underwent successful reperfusion therapy were randomized on day 1 to intracoronary bone marrow autologous mononuclear.

Autologous bone marrow mononuclear cell therapy is safe and promotes amputation- free survival in patients with critical limb ischemia Michael P. Murphy,

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program by Michael.

PROACT-4 Trial design: Patients enroute to the hospital with acute chest pain were randomized to point of care troponin testing (n = 305) vs. usual care.

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those

POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.

Volume 14, Issue 2, Pages (February 2014)

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.

BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.

ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

After Eighty Study Trial design: Elderly patients with non–ST-elevation acute coronary syndrome (NSTE-ACS) were randomized to invasive therapy (n = 229)

(p-value between groups = 0.59)

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p < for noninferiority)

Volume 20, Issue 6, Pages (June 2012)

Ezetimibe/simvastatin

(p for noninferiority < 0.001)

(p = for noninferiority)

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

ACCELERATE Trial design: Patients at high vascular risk were randomized to either evacetrapib 130 mg daily or placebo. They were followed for 30 months.

POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived.

ARISE Trial Aggressive Reduction of Inflammation Stops Events

TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Eduardo Marbán, MD, PhD Mayo Clinic Proceedings

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

(p for noninferiority = 0.01)

MATRIX: Radial vs. Femoral

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

(p for non-inferiority < 0.001)

Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period,

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Presentation transcript:

MOBILE Trial design: Patients with critical limb ischemia were randomized to intramuscular injection of bone marrow-derived stem cells (n = 119) vs. placebo injection (n = 36). (p = 0.33) Results Serious adverse events: 59% of the stem cell group vs. 69% of the placebo group (p = 0.33) Death or amputation: 20% of the stem cell group vs. 31% of the placebo group (p = 0.22) 69 59 % Conclusions Among patients with critical limb ischemia, intramuscular injection of bone marrow-derived stem cells was feasible This small pilot study demonstrated the safety of stem cell injection Stem cell Placebo Presented by Dr. Michael P. Murphy at AHA 2016